Half Year 2021 Valneva SE Earnings Call Transcript
Good day, and thank you for standing by, and now Valneva presents its Half Year 2021 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your host today, CEO of Valneva Thomas Lingelbach. Please go ahead.
Good day, everyone. Welcome to our report on H1 '21 financials and general business update. While the first half of 2021 has been marked by tremendous success on our R&D side of the business, we have nicely delivered against our key major R&D objectives, and of course, the most recent news flow, probably at this moment in time, the most important one is related to our chikungunya vaccine. We are very proud to be the first company in the world that has successfully delivered a Phase III for a chikungunya vaccine, which continues to be a significant unmet medical need.
We made excellent progress on our other clinical assets
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |